Back to today’s briefing

Story perspectives

New Drug Promises 50% Alzheimer's Risk Reduction, Experts Caution

3/25/2025

25 3

Summary

Story summary

A groundbreaking study from Washington University in St. Louis suggests that the anti-amyloid drug gantenerumab could cut the risk of familial Alzheimer's disease by 50%. Yet, experts urge caution, highlighting the study's limitations and the intricate nature of Alzheimer's, calling for more extensive research to validate these promising results.

1 of 1

Story summary

A groundbreaking study from Washington University in St. Louis suggests that the anti-amyloid drug gantenerumab could cut the risk of familial Alzheimer's disease by 50%. Yet, experts urge caution, highlighting the study's limitations and the intricate nature of Alzheimer's, calling for more extensive research to validate these promising results.